Determination of atazanavir in human plasma by high-performance liquid chromatography with UV detection

Journal of Chromatographic Science

Volumn 46, Issue 6, 2008, Pages 485-489

  Cattaneo, Dario ^a,b,c   Maggiolo, Franco ^a   Ripamonti, Diego ^a   Perico, Norberto ^a,b  

^a OSPEDALI RIUNITI   (Italy)

^b Chiara Cucchi De Alessandri and Gilberto Crespi

^c MARIO NEGRI INST PHARMACOL RES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMBYSTOMA TIGRINUM STEBBENSI VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 47549105933     PISSN: 00219665     EISSN: None     Source Type: Journal    
DOI: 10.1093/chromsci/46.6.485     Document Type: Article

References (17)

1. J.A. Pineda, R. Palacios, A. Rivero, L. Abdel-Kadel, M. Marquz, P. Cano, J.A. Mira, J. Torre-Cisneros, F. Lozano, and J. Santos. Low incidence of severe liver toxicity in patients receiving antiretroviral combinations including atazanavir. J. Antimicrob. Chemother. 57: 1016-17 (2006).
2. T. Swainston Harrison and L.J. Scott. Atazanavir: a review of its use in the management of HIV infection. Drugs. 65: 2309-36 (2005).
3. (No authors listed). Some PIs have greater impact than others on heart disease. Patients on atazanavir had less heart problems. AIDS Alert. 21: 17-18 (2006).
4. A. Le Tiec, C. Barrail, C. Goujard, and A.M. Taburet. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin. Pharmacokinet. 44: 1035-50 (2005).
5. S. Smith, D.E. Jeganathan, and J. Ray. Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrations. HIV Clin. Trials 7: 34-38 (2006).
6. S. Colombo, N. Guignard, C. Marzolini, A. Telenti, J. Biollaz, and L.A. Decosterd. Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after solid-phase extraction. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 810: 25-34 (2004).
7. E. Dailly, F. Raffi, and P. Jolliet. Determination of atazanavir and other antiretroviral drugs plasma levels by high performance liquid chromatography with UV detection. J. Chromatogr. B Analyt Technol. Biomed. Life Sci. 813: 353-358 (2004).
8. R.W. Sparidans, F. Dost, K.M. Crommentuyn, A.D. Huitema, J.H. Schellens, and J.H. Beijnen. Liquid chromatographic assay for the protease inhibitor atazanavir in plasma. Biomed. Chromatogr. 20: 72-76 (2006).
9. O. Tribut, M.C. Verdier, C. Arvieux, H. Allain, C. Michelet, and D. Bentue-Ferrer. Simultaneous quantitative assay of atazanavir and 6 other HIV protease inhibitors by isocratic reversed-phase liquid chromatography in human plasma. Ther. Drug Monit. 27: 265-69 (2005).
10. R. Verbesselt, E. Van Wijngaerden, and J. de Hoon. Simultaneous determination of 8 HIV protease inhibitors in human plasma by isocratic high-performance liquid chromatography with combined use of UV and fluorescence detection: Amprenavir, indinavir, atazanavir, ritonavir, lopinavir, saquinavir, nelfinavir and M8-nelfinavir metabolite. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 845: 51-60 (2007).
11. A. Schuster, S. Burzawa, M. Jemal, E. Loizillon, P. Couerbe, and D. Whigan. Quantitative determination of the HIV protease inhibitor atazanavir (BMS-232632) in human plasma by liquid chromatography-tandem mass spectrometry following automated solid-phase extraction. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 788: 377-86 (2003).
12. FDA guidance for industry, Center for Drug Evaluation and Research, US Department for Health and Human Services, May (2001).
13. D. Ripamonti, D. Cattaneo, F. Maggiolo, M. Airoldi, L. Frigerio, P. Bertuletti, M. Ruggeri, and F. Suter. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS, 21: 2409-2415 2007.
14. A. Loregian, S. Pagni, E. Ballarin, E. Sinigalia, S.G. Parisi, and G. Palù. Simple determination of the HIV protease inhibitor atazanavir in human plasma by high-performance liquid chromatography with UV detection. J. Pharm. Biomed. Anal. 42: 500-505 (2006).
15. J.M. Poirier, P. Robidou, and P. Jaillon. Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma by reversed-phase liquid chromatography. Ther Drug Monit 27: 186-92 (2005).
16. U. Seshachalam, D.V.L. Narasimha, B. Haribabu, and K.B. Chandrasekhar. Determination of atazanavir in the presence of its degradation products by a stability-indicating LC method. Chromatographia 65: 355-58 (2007).
17. K. Michalik, Z. Drzazga, A. Michnik, and M. Kaszuba. Thermal stability study of the protease inhibitors nelfinavir and atazanavir sulfate. J. Therm. Anal. Cal. 88: 401-404 (2007).